



Annual Report

2024-2025



CHILD CANCER
RESEARCH FOUNDATION

Funding research into childhood
cancers for over forty years

Contents

4 Committee of Management

Meet our Committee of Management Team who are the driving force behind the directions we take.

5 Stats & Achievements

A snapshot of our Foundation's funding and fundraising in the 2024/2025 financial year.

6 Funding of Grants

Read about the research projects funded by CCRF in 2024/2025 financial year.

14 CCRF Lab Report

Scientific reports direct from our CCRF Funded Scientists in the WA Kids Cancer Centre.

26 Financial Statements

We report on the 2024/2025 financial year.



A message from The Foundation

The 2024–2025 financial year marked a period of renewal and positive momentum for the Child Cancer Research Foundation. It was a year shaped by strengthened leadership, deepening partnerships and a clear focus on supporting the children and families who inspire our mission every day.

In September 2024, several new members joined the Committee of Management, bringing a wealth of knowledge, lived experience and professional expertise to the Foundation. Soon after, we honoured Chairman Geoff Cattach AM, whose remarkable 41 years of service helped shape the history, impact and reputation of CCRF. His legacy continues to guide our purpose. Leadership transitioned confidently in January 2025, with Tracy Hollington appointed Chairperson, supported by Belinda Ramshaw as Secretary and Justin Bruce continuing as Treasurer.

This refreshed governance strengthened the Foundation's strategic direction and reinforced our commitment to accountability, transparency and long-term stability. Each member of the Committee brings unique insight, including lived experience with childhood cancer, strong governance capability, business leadership, survivor advocacy and a deep understanding of CCRF's legacy. This combination of skills and perspectives positions the Foundation well for the years ahead.

Throughout the year, CCRF continued to deliver on its core mission by funding critical research at the WA Kids Cancer Centre, part of The Kids Research Institute Australia. CCRF provided \$434,458 to support pioneering research led by Associate Professor Rishi Kotecha, Dr Laurence Cheung and Dr Sébastien Malinge. These long-term research programs continue to drive improvement in treatment, survivorship and outcomes for children diagnosed with cancer.

An important milestone during this period was the transition of the Back on Track WA Program into the independent Back on Track Foundation. Under the leadership of COO Kylie Dalton, the program has grown significantly and now operates as its own charity while continuing to work closely alongside CCRF. This evolution reflects the strength and impact of the education advocacy model that CCRF first helped establish more than a decade ago.

Community engagement also continued to build throughout the year. Giving Month 2025 raised \$167,950, one of the Foundation's strongest results in recent years and a testament to the generosity of donors, families and supporters across Western Australia. The Foundation received 589 donations from both new and returning supporters, each one representing a personal commitment to helping children survive and thrive.

A significant highlight of the year was CCRF's participation in the Childhood, Adolescent and Young Adult Cancer Ministerial Roundtable in Canberra, hosted by Cancer Australia. Joining national leaders, researchers, policymakers and sector advocates, CCRF was able to represent Western Australian families and share insights drawn from decades of community connection and research investment.

Being at the table for these discussions is essential. It ensures that the needs of WA children are heard, that our state remains aligned with national priorities and that CCRF continues to contribute to collaborative efforts focused on improving outcomes for young people affected by cancer. Our involvement reaffirmed CCRF's role as an informed, respected and active voice in the childhood cancer sector.

As we look to the year ahead, we do so with optimism and confidence. With renewed governance, strengthened operational support through our long-standing partnership with Absolute Edge Media, and expanding engagement across businesses and community organisations, CCRF is well positioned for continued growth. Preparations for the 2025 Keep the Flame Alive Quiz Night are already showing strong interest from corporate and community partners.

We remain deeply grateful to everyone who stands with us. Your support allows us to continue funding research that brings hope to children and families across Western Australia. Together, we look forward to building brighter futures for children diagnosed with cancer, one discovery, one breakthrough and one child at a time.

With appreciation and hope,



Tracy Hollington
CHAIRPERSON



Andrea Alexander
CHIEF EXECUTIVE OFFICER

Committee of Management

AS AT 30/06/2025




Geoffrey Cattach, AM
CHAIRMAN
(Until January 2025)



Tracy Hollington
CHAIRPERSON
(From January 2025)



Justin Bruce
TREASURER




Belinda Ramshaw
SECRETARY
(From January 2025)



Andrea Alexander



Natalie Hiddlestone



Tony Carvajal



Georgia Lowry

Founder

Mr Peter Harper

Life Members

Mr Philip Bruce | Mr Geoffrey Cattach, AM | Mr Peter Falconer, OAM
Mr Peter Harper | Professor Ursula Kees | Mr Kim Williamson


Foundation Staff



Andrea Alexander
CHIEF EXECUTIVE OFFICER



Kylie Dalton
CHIEF OPERATING OFFICER
(Until September 2024)



Connie Lee
SUB-CONTRACTOR
IT CONSULTANT



Michele Dalton
SUB-CONTRACTOR
COMMUNICATIONS,
DESIGN & MARKETING

Back on Track Program



Kylie Dalton
PROGRAM DIRECTOR
(Under CCRF until Sept 2024)



Louise Shedden
PROGRAM MANAGER
(Under CCRF until Sept 2024)



Caroline Crofton
SENIOR EDUCATION ADVOCATE
(Under CCRF until Sept 2024)



Janelle Eddy
EDUCATION ADVOCATE
(Under CCRF until Sept 2024)



Stuart Shields
EDUCATION ADVOCATE
(Under CCRF until Sept 2024)



Talia Lackenby
DIGITAL MARKETING
(until 4 July 2024)

Stats & Achievements



Subscriptions	\$2,445
Donations & Promotions	\$143,605
Community Activities	\$55,693
Back on Track WA Program	\$59,391
Raffles & Direct Mail Campaigns	\$24,715
Schools & Associations	\$303
Commercial Support	\$31,439
Gift in Wills	\$194,421
Grants	\$18,000
Interest Received	\$3,562

Scientists Supported

22

Total research funded

More than
\$434k

10 Scientific Publications

5 Student Graduations


1 PHD STUDENT,
1 MASTERS STUDENT,
3 HONOURS STUDENTS

16 Leukaemia Translational Research Team

- 2 Co-Heads,
- 2 Postdoctoral Researchers,
- 4 Research Assistants,
- 5 PhD Students,
- 3 honours Students

6 Translational Genomics in Leukaemia Team

- 1 Head,
- 1 Postdoctoral Researcher,
- 1 Research Assistants,
- 2 PhD Students and
- 1 Honours student



Regular giving
Donations — memorial giving
Donations — workplace giving
Donations via website
Donation/newsletter/other

2024/2025

589
Donations

108 New
478 Existing

Average gift
\$559



Funding of Grants

Leukaemia Translational Research

Triennial Block Grant (2022–2024)

Total Expenditure: **\$281,442**

Researchers: Associate Professor Rishi S Kotecha and Associate Professor Laurence C Cheung

Title: *Module 1 - Novel Therapeutic Agents for Infant Acute Lymphoblastic Leukaemia.*

Title: *Module 2 - Elucidating and Targeting the Crosstalk Between Fat and Leukaemia Cells as a Novel Therapeutic Strategy for Children with High Risk Leukaemia*


CLCRF Ursula Kees Fellow (2022–2024)

Total Expenditure: **\$153,015**

Researcher: Dr Sébastien Malinge

Title: *Towards Improving Prevention, Treatments and Outcomes in Childhood Leukaemia.*

Total Research Funded: **\$434,458**



Scientists Supported

22

10 Scientific Publications

5 Student Graduations

1 PHD STUDENT,
1 MASTERS STUDENT,
3 HONOURS STUDENTS



Total research funded
More than

\$430k

Our Patron

The Foundation is honoured to have the continued support of our Patron, Justin Langer AM, whose commitment and advocacy inspire our community and strengthen the impact of our work.

As a long-standing supporter and passionate advocate for children and families affected by cancer, Justin continues to use his platform to raise awareness and encourage others to get involved. His compassion, integrity and belief in the power of research embody the spirit of the Foundation.

We extend our heartfelt thanks to Justin for his ongoing involvement and for standing alongside us as we work toward a future where every child can live a long and healthy life.



Community Activities & Events

The Foundation's work is powered by the generosity and spirit of Western Australians. Throughout 2024–2025, communities across the state came together in support of childhood cancer research, creating meaningful impact through events, partnerships and grassroots fundraising. Each activity, whether large or small, strengthened CCRF's connection to the people and families we serve.

From regional events to local fundraisers, every contribution helped advance CCRF's mission and strengthened our connection to the families and researchers we serve.




Boarswamp Campdraft Charity Draft

31 December 2024 - The Boarswamp Campdraft community once again demonstrated extraordinary generosity. Hosted at Blythewood Station, the annual Charity Draft raised \$30,000 through auctions, competitions and spirited involvement from riders and families. The event continues to stand out as one of CCRF's most dedicated regional fundraisers, showcasing the strength and heart of rural Western Australia.



Rotary Club of Greater Bunbury

July 2024 - The Rotary Club of Greater Bunbury continued its long tradition of supporting CCRF, presenting a \$10,000 contribution at a community event that highlighted their long-standing commitment to the Foundation. The partnership reflects the importance of regional service clubs in supporting research that improves outcomes for children with cancer.



HBF Run for a Reason

19 May 2025 - Families and supporters braved wet and windy conditions to take part in HBF Run for a Reason, raising \$4,793 for childhood cancer research. Participants walked and ran in CCRF colours, carrying stories of resilience and hope along the Perth course. The event remains a powerful example of community spirit and determination.



Celebrating Survivorship

April 2025 - A community-led event at the Byford Country Club raised \$1,700 in honour of childhood cancer survivor Angus Hollington, marking five years cancer-free. Friends, family and supporters gathered to celebrate Angus' milestone, reflecting the strong connection between CCRF's mission and the families we support.

FoundLab Byford Quiz Night

July 2024 - FoundLab Byford rallied local supporters for a lively quiz night that raised \$1,059. The evening was filled with friendly competition, laughter and community spirit, showing how smaller events can create meaningful impact when local groups unite behind a shared cause.


Community Activities & Events



Containers for Change

Supporters across Western Australia continued to back CCRF through the Containers for Change program, turning everyday recycling into meaningful community impact. Since joining the program, CCRF supporters have raised \$12,042.80, with every dollar helping to fund vital childhood cancer research projects. Each container returned represents a small act of care for both the environment and the children and families we support. There is also positive news for the years ahead.

The State Government has announced that from 1 July 2026, Western Australia's container deposit scheme will expand to include additional drink containers such as juice, cordial and flavoured milk, as well as wine bottles and casks up to three litres. This expansion will create even more opportunities for supporters to recycle, raise funds and contribute to CCRF's mission through this simple and sustainable initiative.



Beyond Bank Community Reward Program

CCRF continued its strong relationship with Beyond Bank through participation in the Community Reward Program. This long-term partnership provides supporters with a simple and meaningful way to give back through their everyday banking. Over the lifetime of the partnership, \$15,365 has been gifted to CCRF, reflecting the power of sustained community connections and purpose-driven corporate support.



Girls Festival of Community Soccer

May 2025 - CCRF proudly participated in the Girls Festival of Community Soccer at Fremantle Oval, engaging with more than 500 players, families and supporters. While not a fundraising event, it offered a valuable opportunity to share CCRF's mission and deepen our connection with sporting communities across the state.



Entertainment Group Support

CCRF's long-standing relationship with The Entertainment Group continued throughout the year. Supporters purchased Entertainment memberships, contributing to ongoing research funding while enjoying local dining, leisure and family experiences. CCRF was also proud to join The Entertainment Group in August 2024 to celebrate 30 years of community fundraising.

Since joining the program, the Foundation has raised more than \$46,000 through the sale of Entertainment Books and digital memberships, demonstrating the value of accessible, community-friendly fundraising partnerships.

The Foundation Team

The 2024–2025 financial year marked a period of renewal for the Foundation's team and governance. With refreshed leadership, strengthened operations and growing community engagement, CCRF continued to build the foundations for a strong and sustainable future.

Chief Executive Officer Andrea Alexander and Chief Operating Officer Kylie Dalton led this work with dedication and stability. Their combined experience continues to guide the Foundation with clarity, consistency and a deep commitment to improving outcomes for children facing cancer.

Strengthened Governance and Leadership

The Foundation's governance was further strengthened by the appointment of experienced and passionate members to the Committee of Management. Each brings valuable skills, lived experience and community insight that enhance CCRF's direction.

Tracy Hollington, Chairperson

Tracy brings strong governance capability, a background in law and significant lived experience as the mother of childhood cancer survivor Angus Hollington. Her understanding of the emotional, medical and educational challenges families face gives her leadership depth, compassion and clarity. Tracy's combination of legal knowledge, governance experience and lived perspective ensures the Foundation is guided with integrity and insight.

Belinda Ramshaw, Secretary

Belinda is a childhood cancer survivor whose personal experience underpins her commitment to improving outcomes for children and families. She holds an MBA and serves as the WA State Manager for the Governance Institute of Australia, bringing exceptional strategic, governance and organisational expertise to the Board. Belinda's lived experience and professional capabilities make her a vital voice in shaping CCRF's future.

Natalie Hiddlestone, Committee Member

Natalie brings more than 25 years of connection to CCRF, having first joined the Board in 2000. As a long-time business owner and community leader, she offers extensive organisational knowledge, practical insight and a deep understanding of the Foundation's history and evolution. Her return to the Board strengthens continuity and ensures valuable historical context is preserved as CCRF grows.

Georgia Lowry, Committee Member

Georgia has been a long-time ambassador for CCRF. Diagnosed with leukaemia as a baby, her story has been part of the Foundation's identity for decades. Now formally serving on the Board, Georgia brings a unique perspective as a survivor, advocate and community leader. Her insight strengthens CCRF's understanding of survivorship and long-term needs.

Tony Carvajal, Committee Member

Tony is a respected business owner with a strong background in community-led initiatives. His experience working with local organisations and his understanding of small business operations add practical insight to the Board. Tony brings a community-focused mindset and a commitment to supporting causes that create real impact.

Strengthened Operational Capacity

To support the next phase of growth, CCRF re-engaged Absolute Edge Media in October 2024. As a trusted partner for more than 12 years, AEM provides strategic support across communications, design, marketing and fundraising. Early priorities included producing the 2023–2024 Annual Report and coordinating the Celebration of Geoff Cattach AM's remarkable 41 years of leadership.

This strengthened structure has already delivered strong results. Giving Month 2025 raised \$167,950, one of CCRF's best outcomes in recent years and a clear reflection of increasing engagement from donors, businesses and community partners.

Looking Forward

With renewed leadership, expanded operational capacity and a highly engaged Board, the Foundation enters the coming year with confidence. The team remains focused on building partnerships, strengthening fundraising and continuing CCRF's long tradition of funding world-class childhood cancer research.

Together, this committed team is shaping a positive and forward-looking future for the Foundation and the families it exists to support.

In Memory

During the 2024–2025 year, the Foundation honoured several remarkable individuals whose contributions, leadership and generosity helped shape CCRF's history. Their commitment to improving outcomes for children with cancer has left a lasting legacy, and their influence continues to guide the work we do today.



Peter Harper

Peter Harper was the founding force behind the Child Cancer Research Foundation. Motivated by his daughter Jennifer's leukaemia diagnosis in 1977, he recognised the urgent need for dedicated childhood cancer research in Western Australia. In 1979, Peter helped establish what would become the Foundation, laying the groundwork for more than four decades of progress and impact.

With the support of colleague and long-time Chairman Geoff Cattach AM, Peter shaped the Foundation's early direction and helped build the community of donors, families and researchers who would sustain CCRF for generations. His vision, determination and compassion created an organisation that continues to transform outcomes for children today. His legacy is felt in every research breakthrough supported by CCRF.

Dr Peter Dallas

Dr Peter Dallas made significant contributions as both a pioneering researcher and a passionate advocate for childhood brain cancer research. His dedication to scientific advancement influenced the direction of paediatric brain cancer research in Western Australia, and his work continues to impact the lives of children and families.



Brent Cattach

Brent Cattach was a cherished member of the CCRF family whose strength and story have long been part of the Foundation's identity. His journey inspired supporters across Western Australia and reaffirmed CCRF's commitment to funding research that improves survival and long-term wellbeing. Brent's legacy continues through the work CCRF champions today.



Ros Worthington OAM

Ros Worthington was a respected ambassador and long-standing supporter of children's health and community causes. Her compassion, advocacy and tireless dedication elevated awareness of childhood cancer and encouraged others to support research. Ros leaves behind a legacy of kindness and spirited community leadership.



Eric Maddock

Eric Maddock was a dedicated supporter of CCRF whose involvement spanned more than a decade. Since 2013, Eric and his wife Annette have been unwavering contributors to the Foundation through their enthusiastic participation in the South West Bike Trek. From 2017 to 2022, Eric took on the role of Bike Trek Coordinator, leading riders and volunteers with generosity, commitment and steady determination.

His efforts strengthened one of CCRF's most recognisable community fundraising traditions, and his contribution has left a lasting legacy across the South West and beyond. Eric's kindness, leadership and dedication remain deeply appreciated by everyone connected to the Bike Trek and the Foundation.

Their lives, generosity and belief in the importance of research will continue to inspire the CCRF community for years to come.

Gifts in Wills/Endowment Fund

Gifts in Wills continue to play an important role in funding the Foundation's long-term research commitments. These special contributions reflect the deep generosity of people who believe in a future where every child can live a long and healthy life after cancer.

During 2024–2025, CCRF received \$194,421 through bequests and an endowment donation. Most of these gifts were unexpected, discovered only after the passing of their kind benefactors. Their foresight and compassion will leave a lasting legacy for children and families affected by cancer.

CCRF extends its heartfelt thanks to the following supporters for their extraordinary generosity:

Bequest Donors

- + Allan Barber
- + Marjorie V. Brown
- + Amy Rose Cooke
- + Pamela Templeton
- + Dieter Theil

Total gifts

More than

\$194k

Endowment Fund

- + Margaret Stevenson Endowment Fund

These legacies are more than financial gifts. They are enduring acts of kindness that continue to drive the research needed to change children's lives for generations to come.

Benefactors

The Foundation remains deeply grateful to the individuals, families and organisations whose generosity continues to make our work possible.

During 2024–2025, CCRF received \$84,679 in donations from a mix of long-standing supporters and new benefactors who joined our mission to fund world-class childhood cancer research.

Our sincere thanks go to the following major benefactors for their continued trust and generosity:

Major Benefactors

- + Clark Family Trust
- + Margaret Miller Foundation
- + The Stan Perron Charitable Foundation Ltd

Our continued thanks to these very generous supporters for their ongoing support of the Foundation over many years.





Corporate Benefactors

Corporate partners also played a vital role this year, providing both financial and in-kind support that strengthens CCRF's capacity to fund life-changing research.

Corporate Supporters

- + Beyond Bank
- + Lotterywest
- + Statewide Bearings
- + Ron Porto Pty Ltd
- + BusinessAg
- + Dempers & Seymour Pty Ltd
- + Woolworths Group Ltd

Each partnership represents a shared belief in progress, community and compassion. Together, our benefactors and corporate supporters help ensure that more children survive their cancer diagnosis and go on to live long, healthy lives.

Membership

The Foundation's members remain the heart of our organisation. Their commitment, advocacy and financial support provide a strong foundation for the work we do and help ensure that vital research into childhood cancers continues year after year.

During 2024–2025, membership numbers declined slightly, reflecting a wider trend across the not-for-profit sector. Despite this, our members' loyalty and belief in the Foundation's mission continue to drive our efforts forward.

Recognising the importance of an active and engaged membership, CCRF is exploring new ways to attract and retain members. In the year ahead, we will focus on clearer communication, stronger engagement opportunities and renewed recognition for those who choose to support the Foundation as financial members.

The introduction of corporate membership levels presents an exciting opportunity to strengthen ties with the business community.



By becoming corporate members, organisations can demonstrate their social responsibility while directly contributing to research that changes children's lives.

We thank every member for their continued dedication and support. Your involvement keeps the Foundation strong and helps create a future filled with hope for children and families affected by cancer.

Conclusion & Outlook

The Australian charitable sector continues to evolve within a dynamic environment marked by rising operational costs, shifting donor behaviour and increasing community needs. Despite these pressures, charities remain a vital force for research, support and long-term impact, and CCRF is proud to contribute meaningfully to this landscape through the generosity and commitment of its supporters.

For the Child Cancer Research Foundation, 2024–2025 was a year defined by renewed direction, stronger partnerships and growing community engagement. With refreshed governance and strengthened operational capability, the Foundation continued to deliver on its core purpose of funding pioneering research at the WA Kids Cancer Centre, part of The Kids Research Institute Australia. These ongoing research programs provide stability for clinical teams and continue to advance treatment and survivorship pathways for children diagnosed with cancer.

Community support remained a major source of strength throughout the year. From the Boarswamp Campdraft Charity Draft raising \$30,000, to regional Rotary Clubs hosting events that championed CCRF's mission, to families and supporters participating in HBF Run for a Reason, every effort reflected the dedication of individuals, businesses and community groups who believe in the power of research to change children's lives. Fundraisers held in honour of childhood cancer survivors, including the celebration for Angus Hollington, further highlighted the strong connection between CCRF and the families it supports.

The year also saw generous contributions through the Containers for Change initiative, long-standing support from the Entertainment Group, increasing participation from corporate partners, and valuable awareness-building opportunities such as the Girls Festival of Community Soccer. Together, these initiatives demonstrate the broad and growing network of people who stand behind the Foundation.

A significant milestone for CCRF this year was its participation in the Childhood, Adolescent and Young Adult Cancer Ministerial Roundtable in Canberra. Representing Western Australian children, families and researchers in this national forum ensures CCRF remains an active voice in shaping sector priorities and contributing to collaborative efforts focused on



improving outcomes across Australia. Being part of these discussions highlights the importance of working together to advance research and provide stronger pathways for young people facing cancer.

Building on this, engagement continued to rise throughout the year. Giving Month 2025, which raised \$167,950, showcased the collective generosity of donors and reaffirmed the community's belief in CCRF's mission. Across the financial year, the Foundation received 589 donations from both new and returning supporters, each representing a powerful commitment to children and families.

Looking ahead, the Foundation enters the next year with confidence. Engagement with businesses, schools and community organisations continues to expand, and preparations for the 2025 Keep the Flame Alive Quiz Night are already generating enthusiasm from corporate and community partners. CCRF remains focused on strengthening partnerships, nurturing supporter relationships and growing its fundraising capacity to further support world-class research.

With renewed leadership, strengthened structures and the continued generosity of the community, CCRF is positioned for a future filled with purpose, progress and hope. Together, we remain committed to delivering research that transforms outcomes for children diagnosed with cancer and supporting the families who stand beside them.



Child Cancer Research

2024/2025

The past year has marked a transformative step forward for the WA Kids Cancer Centre, building on the momentum of our 2023 external review and setting the stage for our future in childhood cancer research.

Informed by the insights of Professor Doug Hilton's comprehensive review of our research strategy, we've taken decisive steps to strengthen the integration between our laboratory research and clinical care. This strategic evolution has culminated in a landmark achievement: securing 10-year funding from the Stan Perron Charitable Foundation, with additional contributions from the Perth Children's Hospital Foundation (PCHF) and The University of Western Australia, to establish the WA Comprehensive Kids Cancer Centre.

The Centre envisions a future where all kids with cancer survive and thrive, through a collaboration integrating the clinical excellence delivered at Perth Children's Hospital and the research expertise of The Kids Research Institute Australia and The University of Western Australia.

It will act as a springboard to supercharge all research across our Cancer Centre – bringing together our strengths in laboratory science, clinical care, and translational research under a unified, strategic framework. However, this would not have been possible without the decades of support from CCRF – your support has been critical to our success.

By aligning our work within core research themes – each focused on improving care for children today and developing new treatments for tomorrow – we're aiming to create a foundation for long-term impact.

Within this new structure, our commitment to translational research remains unwavering. This year, our leukaemia teams, supported by CCRF, have continued to make significant strides in developing new immunotherapies and treatment pathways for children with leukaemia.



These innovations reflect our consistent goal, to ensure every child diagnosed with cancer has access to the most effective, least toxic treatments possible.

We continue to work closely with families, clinicians, and community partners to ensure our research is grounded in real-world needs and delivers tangible outcomes.

We are excited to be bringing Team WA together through the WA Comprehensive Kids Cancer Centre. The contributions of CCRF and their incredible supporters are critical to this partnership.

We are deeply grateful to the Child Cancer Research Foundation and their supporters, who have enabled our researchers to push boundaries, ask bold questions, and ultimately, create a future where all children with cancer survive and thrive.

Associate Professor Joost Lesterhuis


HEAD, WA KIDS CANCER CENTRE

THE KIDS RESEARCH INSTITUTE AUSTRALIA

Leukaemia Translational Research

Funding: Triennial Block Grant (2022–2024)

Researchers: Associate Professor Rishi S Kotecha and
Associate Professor Laurence C Cheung




Leukaemia is the most frequently occurring type of childhood cancer. International research over the past 70 years has led to massively improved cure rates. However, despite these advances, leukaemia continues to be one of the leading causes of disease-related death in Australian children.

The main goal of our Leukaemia Translational Research laboratory is to identify new therapeutic approaches so that we can continue to improve the outcomes of children suffering from leukaemia worldwide. The Leukaemia Translational Research team is co-led by Professor Rishi Kotecha and Associate Professor Laurence Cheung. In 2025, Dr Vincent Kuek and Dr Sung-Kai Chiu further established themselves as post-doctoral officers within the team, with Joyce Oommen and Emanuela Ferrari maintaining their key roles as research assistants.



Supervision and mentoring of the next generation of researchers continues through the groups' students. In 2025 our PhD candidates were Taylor Ferguson, Stephen Dymock and Abigail Lim. Yasmin Henderson Kelly and Haima Jayasankar joined us as our Honours students. The key achievements of the Leukaemia Translational Research team are highlighted in the following pages.

Module 1: Novel Therapeutic Agents for Infant Acute Lymphoblastic Leukaemia



Newborns and babies who are diagnosed with B-cell acute lymphoblastic leukaemia (B-ALL) at less than 12 months of age face a dismal outlook. Translocations of the KMT2A (MLL) gene are present in up to 80% of ALL cells from infants, with 5-year event-free survival of less than 40%. In an attempt to find better treatments for these infants, international study groups have conducted many therapeutic studies with more intensive therapy. Unfortunately, this led to a large number of toxicity-related deaths and did not improve overall survival. Novel strategies are urgently required to improve outcomes.

CCRF have been long-standing funders of our work to develop innovative treatments to improve outcomes for infants with acute lymphoblastic leukaemia. The achievements within this research module have generated a number of research publications and allowed us to leverage additional funding to support the work, the details

of which are provided on pages to follow.

We would like to sincerely thank CCRF for the support they have offered over the years, with the knowledge that the funding has fostered development of Professor Kotecha's research into this field, which has ultimately led to improved survival outcomes for infants with B-ALL following the addition of a novel immunotherapy, blinatumomab, to treatment.

These findings have provided the platform to replace highly toxic chemotherapy with immunotherapy. As such, we have subsequently developed two new global clinical trials for infants with B-ALL. In the Interfant-21 study all patients will (i) receive at least once cycle of blinatumomab, (ii) one of the chemotherapy cycles will be replaced by a second cycle of blinatumomab for certain patients, and (iii) we will avoid the administration of excessive chemotherapy by capping the

dose of pegasparginase for all infants at 1500 IU/m². This trial is now open and available for infants diagnosed with ALL in Australia and New Zealand. Professor Kotecha has been appointed co-chair of the COG AALL2321 clinical trial, which is investigating the addition of a new agent, venetoclax, to a blinatumomab and chemotherapy backbone in an effort to further improve outcomes.

Notably, some of the preclinical evidence for use of venetoclax in infants with KMT2A-rearranged ALL was generated by our laboratory and was made possible through CCRF funding (Cheung LC et al. Leukemia 2023). These global achievements would not have been possible without the support provided by CCRF over the years.

Additional Funding Leveraged

- Toby FCC Research Grant (2025): Improving outcomes for children with high-risk leukaemia (Kotecha RS, Cheung LC \$200,000)
- WA Child Research Fund (2025-2027): Novel therapeutic strategies to improve the outcome for infants with acute lymphoblastic leukaemia (Kotecha RS, Cheung LC \$599,772)
- National Health and Medical Research Council Investigator Grant (2025-2029): Emerging Leadership 2 (Kotecha RS, \$1,483,020)

CCRF supported publications relevant to this Module

- Faulk KE, Kairalla JA, Hibbitts E, Long-Boyle J, Devidas M, August A, Gore L, Raetz E, Hunger SP, Loh ML, Teachey DT, Brown P, Breese EH, Kotecha RS, Guest E. Age-based pegaspargase dosing is safe and achieves therapeutic levels in infants with ALL: report from COG AALL15P1. *Blood Advances* 2025.
- Gao W, Karsa M, Xiao L, Spurling D, Karsa A, Ronca E, Bongers A, Guo X, Mayoh C, Azfar M, Verhelst SHL, Tanaka K, Cheung LC, Kotecha RS, Lock RB, Burns MR, Vangheluwe P, Norris MD, Haber M, Somers K. Polyamine depletion limits progression of acute leukaemia. *International Journal of Cancer* 2025;156(12):2360-2376.
- Chiu SK, Ferrari E, Oommen J, Malinge S, Cheung LC, Kotecha RS. Preclinical assessment of dactinomycin in KMT2A-rearranged infant acute lymphoblastic leukemia. *Cancers* 2025;17(3):527.
- Kotecha RS, Pieters R, Stutterheim J. KMT2A-rearranged acute lymphoblastic leukaemia. *EJC Paediatric Oncology* 2024;4:100204.
- Brighita LJ, Mondelaers V, Liu Y, Albertsen BK, Zalewska-Szewczyk B, Rizzari C, Kotecha RS, Pieters R, Huitema ADR, van der Sluis IM. Pharmacokinetics of PEGasparaginase in infants with acute lymphoblastic leukemia. *Pharmaceutical Research* 2024;41(4):711-720.
- Karsa M, Xiao L, Ronca E, Bongers A, Spurling D, Karsa A, Cantilena S, Mariana A, Failes TW, Arndt GM, Cheung LC, Kotecha RS, Sutton R, Lock RB, Williams O, de Boer J, Haber M, Norris MD, Henderson MJ, Somers K. FDA-approved disulfiram as a novel treatment for aggressive leukemia. *Journal of Molecular Medicine (Berlin)* 2024;102(4):507-519.
- Mironova D, Saraswati CM, Downie P, Lai CY, Cook E, Carruthers V, Moukhaiber P, Molloy F, Serov J, McKinnon E, Alvaro F, Osborn M, Revesz T, Prestidge T, Cross S, Bateman CM, Moore AS, Khaw SL, Mateos MK, Kotecha RS. Late effects in survivors of infant acute lymphoblastic leukaemia – a study of the Australian and New Zealand Children's Haematology/Oncology Group. *Blood Cancer Journal* 2023;13(1):150.
- van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, Stary J, Ferster A, Brethon B, Locatelli F, Schrappe M, Scholte-van Houtem PE, Valsecchi MG, Pieters R. Blinatumomab added to upfront chemotherapy in infant lymphoblastic leukemia. *New England Journal of Medicine* 2023;388(17):1572-1581.
- Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged ALL reveals a new therapeutic strategy. *Leukemia* 2023;37(1):61-71.
- Kotecha RS. Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy. *Hematology* 2022(1):611-617.
- Isobe T, Takagi M, Sato-Otsubo A, ...Kotecha RS, Cruickshank MN, ...Aburatani H, Ogawa S, Takita J. Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia. *Nature Communications* 2022;13(1):4501.
- Xiao L, Karsa M, Ronca E, Bongers A, Kosciulek A, El-Ayoubi A, Revalde JL, Seneviratne JA, Cheung BB, Cheung LC, Kotecha RS, Newbold A, Bjelosevic S, Arndt GM, Lock RB, Johnstone RW, Gudkov AV, Gurova KV, Haber M, Norris MD, Henderson MJ, Somers K. The combination of curaxin CBL0137 and histone deacetylase inhibitor panobinostat delays KMT2A-rearranged leukaemia progression. *Frontiers in Oncology* 2022;12:863329.
- Karsa M, Ronca E, Bongers A, Mariana A, Moles E, Failes TW, Arndt GM, Cheung LC, Kotecha RS, Kavallaris M, Haber M, Norris MD, Henderson MJ, Xiao L, Somers K. Systematic in vitro evaluation of a library of approved and pharmacologically active compounds for the identification of novel candidate drugs for KMT2A-rearranged leukemia. *Frontiers in Oncology* 2022;11:779859.
- Breese EH, Kotecha RS, Guest EM. Acute lymphoblastic leukemia in infants: A distinctive, high-risk subtype of childhood acute lymphoblastic leukemia. In Litzow MR, Raetz EA, eds. *Clinical Management of Acute Lymphoblastic Leukemia: From Bench to Bedside*. Springer 2022;135-148.
- Stutterheim J, de Lorenzo P, van der Sluis IM, ...Kotecha RS, ...Schrappe M, Valsecchi MG, Pieters R. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol. *European Journal of Cancer* 2022;160:72-79.
- Symeonidou V, Jakobczyk H, Bashanfer S, Malouf C, Fotopoulou F, Kotecha RS, Anderson RA, Finch AJ, Ottersbach K. Defining the fetal origin of MLL-AF4 infant leukemia highlights specific fatty acid requirements. *Cell Reports* 2021;37(4):109900.
- Cheung LC, de Kraa R, Oommen J, Chua GA, Singh S, Hughes AM, Ferrari E, Ford J, Chiu SK, Stam RW, Kees UR, Malinge S, Kotecha RS. Preclinical evaluation of carfilzomib for infant KMT2A-rearranged acute lymphoblastic leukemia. *Frontiers in Oncology* 2021;11:631594.



- Stutterheim J, Van der Sluis IM, De Lorenzo P, ...Kotecha RS, ...Szczepanski T, Valsecchi MG, Pieters R. Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the Interfant-06 protocol. *Journal of Clinical Oncology* 2021;39(6):652-662.
- Wander P, Cheung LC, Pinhancos SS, Jones L, Kerstjens M, Arentsen-Peters STCJM, Singh S, Chua GA, Castro PG, Schneider P, Dolman MEM, Koopmans B, Molenaar JJ, Pieters R, Zwaan CM, Kotecha RS,* Stam RW.* Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. *Leukemia* 2020;34(11):2898-2902.
- Cheung LC, Cruikshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS. Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia. *Haematologica* 2019;104(7):e300-e303
- Pieters R, De Lorenzo P, Ancliffe P, ...Kotecha RS, ...Vora A, Schrappe M, Valsecchi MG. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study. *Journal of Clinical Oncology* 2019;37(25):2246-2256.
- Cruickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, Failes TW, Arndt GM, Smithers N, Prinjha RK, Anderson D, Carter KW, Gout AM, Lassmann T, O'Reilly J, Cole CH, Kotecha RS, Kees UR. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin. *Leukemia* 2017;31(1):40-50.
- Kotecha RS, Gottardo NG, Kees UR, Cole CH. The evolution of clinical trials for infant acute lymphoblastic leukemia. *Blood Cancer Journal* 2014;4(4):e200.
- Kotecha RS, Ford J, Beesley AH, Anderson D, Cole CH, Kees UR. Molecular characterization of identical, novel MLL-EPS15 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia. *Haematologica* 2012;97(9):1447-1450.
- Kotecha RS, Murch A, Kees U, Cole CH. Pre-natal, clonal origin of t(1;11)(p32;q23) acute lymphoblastic leukemia in monozygotic twins. *Leukemia Research* 2012;36(1):46-50.

Module 2: Elucidating and targeting the crosstalk between fat and leukaemia cells as a novel therapeutic strategy for children with high-risk leukaemia



Recognising that the tumour microenvironment (cells that neighbour cancer cells) contributes to treatment failure or success has led to a recent paradigm shift in cancer therapy. The tumour microenvironment is well documented to be a key factor in multiple stages of cancer progression. Over the past 20 years, clinical studies in children diagnosed with ALL have clearly demonstrated defects in the bone marrow microenvironment, e.g. loss of fat cells and bone cells. However, little is known with regards to how these bone marrow cells contribute to leukaemia development and disease progression.

With the support of CCRF, we have investigated the role of the different types of bone marrow cells during development of B-ALL. The cell types that we have focused on are bone forming cells (osteoblasts), bone eating cells (osteoclasts), fat cells (adipocytes), blood vessel

cells (endothelial cells) and cells that produce fat cells and bone forming cells (mesenchymal stem cells). In 2024, we completed an investigation into the therapeutic targeting of bone eating cells during B-ALL progression. This study was published in *Blood Cancer Journal*, one of the leading journals in haematology. Furthermore, these findings were accepted for an oral presentation at a prestigious conference, the European School of Hematology - 5th Scientific Workshop: the Haematological Tumour Microenvironment and Its Therapeutic Targeting, which was held in February 2025 in London. A/Professor Laurence Cheung's presentation was well received by the audience and we are delighted that our research findings have drawn significant interest at an international level.

Collaboration is a cornerstone of our research program. We partnered with Regeneron Pharmaceuticals,

a leading biotechnology company based in the USA to access a novel therapeutic agent for our leukemia studies. Through this collaboration, we discovered the importance of the bone forming cells during development of B-ALL. Therapeutic targeting of these cells in our preclinical disease models demonstrated a clear clinical benefit in terms of bone health.

The achievements within this research module have been accomplished due to the long-standing support of the CCRF. This has generated a number of research publications and allowed us to leverage additional funding to support the work, the details of which are provided on following pages.


Additional Funding Leveraged

- Tour de Cure, Local Grant 2025: New therapeutic opportunities for children with high-risk leukaemia (Cheung LC \$10,000)
- Government of WA, WA Near-miss Award 2024: Deciphering the role of bone marrow fat cells in children with high-risk leukaemia (Cheung LC \$100,000)

CCRF supported publications relevant to this Module

- Kotecha RS, Trinder SM, Hughes AM, Mullin BH, Rashid S, Yuan J, Xu J, Duncan O, Skut P, Chua GA, Singh S, Oommen J, Lock RB, Kees UR, Malinge S, Kuek V, Cheung LC. Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia. *Blood Cancer Journal* 2025;15(1):25.
- Hughes AM, Kuek V, Oommen J, Kotecha RS, Cheung LC. Murine bone-derived mesenchymal stem cells undergo molecular changes after a single passage in culture. *Scientific Reports* 2024;14(1):12396.
- Panting RG, Kotecha RS, Cheung LC. The critical role of the bone marrow stromal microenvironment for the development of drug screening platforms in leukemia. *Experimental Hematology* 2024;133:104212.
- Hughes AM, Kuek V, Oommen J, Chua GA, Van Loenhout M, Malinge S, Kotecha RS, Cheung LC. Characterization of mesenchymal stem cells in pre-B acute lymphoblastic leukemia. *Frontiers in Cell and Developmental Biology* 2023;11:1005494.
- Hughes AM, Kuek V, Kotecha RS, Cheung LC. The bone marrow microenvironment in B-cell development and malignancy. *Cancers (Basel)* 2022;14(9):2089.
- Kuek V, Hughes AM, Kotecha RS, Cheung LC. Therapeutic targeting of the leukaemia microenvironment. *International Journal of Molecular Sciences* 2021;22(13):6888.
- Anderson D, Skut P, Hughes AM, Ferrari E, Tickner J, Xu J, Mullin BH, Tang D, Malinge S, Kees UR, Kotecha RS,* Lassmann T,* Cheung LC.* The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolution. *Scientific Reports* 2020;10(1):19173.
- Kotecha RS, Cheung LC. Targeting the bone marrow microenvironment: a novel therapeutic strategy for pre-B acute lymphoblastic leukemia. *Oncotarget* 2019;10(19):1756-1757.
- Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, Oommen J, Wells JE, He B, Singh S, Chua GA, Ford J, Mullighan CG, Kotecha RS,* Kees UR.* New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment. *Leukemia* 2018;32(11):2326-2338.
- Wells JE, Howlett M, Halse HM, Heng J, Ford J, Cheung LC, Samuels AL, Crook M, Charles AK, Cole CH, Kees UR. High expression of connective tissue growth factor accelerates dissemination of leukaemia. *Oncogene* 2016;35(35):4591-4600.
- Wells JE, Howlett M, Cheung LC, Kees UR. The role of CCN family genes in haematological malignancies. *Journal of Cell Communication and Signaling* 2015;9(3):267-278.
- Cheung LC, Strickland DH, Howlett M, Ford F, Charles AK, Lyons KM, Brigstock DR, Goldschmeding R, Cole CH, Alexander WS, Kees UR. Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis. *Haematologica* 2014;99(7):1149-1156.

Funding: CLCRF – Ursula Kees Fellow (2022–2024)
Researcher: Dr Sébastien Malinge
Title: Towards improving prevention, treatments and outcomes in childhood leukaemia



Leukaemia is the most common cancer in children. Each year, more than 280 Australian children aged 0-19 years are diagnosed with leukaemia.

Significant improvements in treatment protocols have led to a survival rate approaching 90% for some subtypes of childhood leukaemia, but despite this success, leukaemia still remains the second leading cause of cancer-related death in Australia. This is mostly due to non-responders and cases of relapse - 1 in 5 children with acute lymphoblastic leukaemia (ALL) and 1 in 3 children with acute myeloid leukaemia (AML) currently relapse. In addition, many survivors suffer from life-threatening conditions due to the toxic treatment they receive. Consequently, these children require longer hospital admissions and ongoing care.

Current treatments have now reached their maximum potential, highlighting the need for novel, better and safer treatments.

These poor outcomes are exemplified in children with Down syndrome (DS), a community of children that experiences a number of additional health issues. Strikingly, up to 3% of children with DS will develop leukaemia during childhood (compared to 0.06% for children without DS). Our lab investigates the mechanisms of leukaemia predisposition, development and response to standard or care treatments, to uncover novel mechanisms and clinically relevant vulnerabilities that can be broadly applied in children with DS and beyond.

Our overarching goal is to develop novel personalised chemotherapy and immunotherapies with increased efficacy and less

toxicity, to better prevent, treat, and cure leukaemia in all children.

Our research program is focused on 3 specific streams:

1. Generate a unique bank of preclinical models to assess novel targeted therapies

We extended our cohort of leukaemia models by validating our 10 new animal models of childhood leukaemia (DS-ALL). Notably, we have also developed 'age-appropriate' models of childhood leukaemia by implanting tumour cells into very young mice to facilitate the testing of novel therapies in the clinically relevant setting of a growing body. From those models, we generated world-first cell lines of DS-ALL that we recently used to investigate the genetic make-up of childhood leukaemia and identify new weaknesses that can be targeted



therapeutically.

Altogether, these tools offer us a platform to test novel chemotherapy and immunotherapy approaches, with the view of selecting the most prominent therapy to be pushed towards clinical trials. We believe our results will translate with greater speed into the clinic and be beneficial for Western Australian children who develop leukaemia.

2. Identified leukaemia cells that resist standard of care treatments

Relapse is a main reason for treatment failure. Children with relapsed leukaemia suffer from life-threatening side-effects induced by treatment, and only 30-50% of them will survive. In most cases, relapse originates from only few cancer cells that resist standard-of-care (SOC) treatment. These SOC-resistant cells are very rare and well hidden within the bone marrow. To identify and characterise these cells, we applied a state of the art single cell approach called CITE-seq. This enables us to identify key features of every individual leukaemic cell that is resistant to SOC treatment. We have now developed new

collaborations to test efficacy of novel immunotherapies that specifically targets these resistant cells; with the view of adding it to SOC treatments to prevent relapse in childhood leukaemia.


3. Discover better and safer therapies in childhood leukaemia: targeting DYRK1A and beyond

In 2024, we reported the efficacy of a new DYRK1A inhibitor in our cell lines of DS-ALL resulting

from a collaborative effort with local, national and international investigators. The chromosome 21 DYRK1A is a key player in many subtypes of childhood leukaemia – myeloid and lymphoid – both associated with Down Syndrome and not.

Several groups across the world, including ours, have demonstrated that targeting this protein is a promising therapeutic approach, alone and in combination with SOC treatments. In brief, we tested efficacy of several new DYRK1A inhibitors and show that LCTB-21 is the most promising one in test tubes and in preclinical animal models. Importantly, a phase I clinical trial using this DYRK1A inhibitor opened in early 2024, and the results will tell us if using this drug in patients is safe.

In parallel, we have screened nine thousand drugs in our DS-ALL cell lines and identified new drugs that we think have a great potential to be translated into the clinic.



Additional funding leveraged (ongoing projects)

- Leukemia and Lymphoma Society – SCOR (2024-2029): Pathogenesis of CRLF2 rearranged acute lymphoblastic leukemia in patients with and without Down Syndrome (co-CI: \$651,525)
- Cancer Council Western Australia – Project Grant (2025-2026): Harnessing the trisomic tumour environment to improve outcomes in DS-leukaemia (\$139,651)
- Tour de Cure – Pioneering grant (2025-2026): Age-specific immune dynamics and therapeutic strategies for childhood acute myeloid leukaemia (\$50,000)
- Cancer Council Western Australia – Project Grant (2025-2026): Enhancing natural killer cell function to combat high-risk B-ALL with Tri-specific Killer Engagers (TriKEs) (co-CI, \$140,000)

Key publications related to the research program

- Panchal K, Armitage J, Cheung LC, Kotecha RS, Malinge S. Perspectives on the origin and therapeutic opportunities in Down syndrome-associated leukemia. *Cancer Metastasis Rev.* 2025 Sep 18;44(4):70.
- Kotecha RS, Trinder SM, Hughes AM, Mullin BH, Rashid S, Yuan J, Xu J, Duncan O, Skut P, Chua GA, Singh S, Oommen J, Lock RB, Kees UR, Malinge S, Kuek V, Cheung LC. Targeting osteoclasts for treatment of high-risk B-cell acute lymphoblastic leukemia. *Blood Cancer J.* 2025 Feb 27;15(1):25.
- Jin Q, Harris E, Myers JA, Mehmood R, Cotton A, Shirnekhi HK, Baggett DW, Wen JQ, Schild AB, Bhansali RS, Klein J, Narina S, Pieters T, Yoshimi A, Pruett-Miller SM, Kriwacki R, Abdel-Wahab O, Malinge S, Ntziachristos P, Obeng EA, Crispino JD. Disruption of cotranscriptional splicing suggests RBM39 is a therapeutic target in acute lymphoblastic leukemia. *Blood.* 2024 Dec 5;144(23):2417-2431.
- Malinge S. Childhood leukaemia in Down's syndrome primed by blood-cell bias. *Nature.* 2024 Oct;634(8032):40-42.
- Carey-Smith SK*, Simad MH*, Panchal K, Aya-Bonilla C, Smolders H, Lin S, Armitage JD, Nguyen VT, Bentley KT, Ford J, Singh S, Oommen J, Laurent AP, Mercher T, Crispino JD, Montgomery AP, Kassiou M, Besson T, Deau E, Meijer E, Cheung LCC, Kotecha RS and Malinge S. Efficacy of DYRK1A inhibitors in novel models of Down syndrome acute lymphoblastic leukemia. *Haematologica.* 2024 Jul 1;109(7):2309-2315.
- Carey-Smith SK, Cheung LCC, Kotecha RS and Malinge S. Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer. *Int J Mol Sc.* 2024 Jun 21;25(13):6815.
- Marques Da Costa ME, Zaidi S, Scoazec JY, Droit R, Lim WC, Marchais A, Salmon J, Cherkaoui S, Morscher RJ, Laurent A, Malinge S, Mercher T, Tabone-Eglinger S, Goddard I, Pflumio F, Calvo J, Redini F, Entz-Werlé N, Soriano A, Villanueva A, Cairo S, Chastagner P, Moro M, Owens C, Casanova M, Hladun-Alvaro R, Berlanga P, Daudigeos-Dubus E, Dessen P, Zitvogel L, Lacroix L, Pierron G, Delattre O, Schleiermacher G, Surdez D, Georger B. A biobank of pediatric patient-derived xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors. *Commun Biol.* 2023 Sep 18;6(1):949.
- Baruchel A, Bourquin JP, Crispino J, Cuartero S*, Hasle H, Hitzler J, Klusmann JH, Izraeli S, Lane AA, Malinge S*, Rabin K, Roberts I, Ryeom S*, Tasian SK, Wagenblast E. Down syndrome and leukemia: from basic mechanisms to clinical advances. *Haematologica.* 2023, July 13. *co corresponding.
- Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. *Leukemia.* 2023 Jan;37(1):61-71.
- Malinge S. It is more `unbalanced` than you think. *Blood.* 2023 Mar 9;141(10):1095-1096.
- Arkoun B, Robert E, Boudia F, Mazzi S, Dufour V, Siret A, Mammasse Y, Aid Z, Vieira M, Aygun I, Aglave M, Cambot M, Petermann R, Souquere S, Rameau P, Catelain C, Diot R, Tachdjian G, Hermine O, Droin N, Debili N, Plo I, Malinge S, Soler E, Raslova H, Mercher T, Vainchenker W. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model. *J Clin Invest.* 2022 Jul 15;132(14):e 156290.
- Bhansali RS, Rammohan M, Lee P, Laurent AP, Wen Q, Suraneni P, Tsai YC, Jenni S, Bornhauser B, Siret A, Fruit C, Pacheco-Benichou A, Harris E, Besson T, Thompson BJ, Goo YA, Hijjiya N, Vilenchik M, Izraeli S, Bourquin JP, Malinge S, and Crispino JD. DYRK1A regulates B-ALL through phosphorylation of FOXO1 and STAT3. *J Clin Invest.* 2021 Jan 4;131(1):e135937.
- Laurent AP, Kotecha R and Malinge S. Gains of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with down syndrome. *Leukemia.* 2020 May 20.
- Laurent AP, Siret A, Ignacimouttou C, Diop MB, Jenni S, Tsai YC, Ross-Weil D, Aid Z, Prade N, Plassard D, Pierron G, Daudigeos-Dubus E, Lecluse Y, Droin N, Bornhauser B, Cheung L, Crispino JD, Gaudry M, Bernard OA, Macintyre E, Barin Bonnigal C, Kotecha R, Georger B, Ballerini P, Bourquin JP, Delabesse E, Mercher T and Malinge S. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell Leukemia. *Clinical Cancer Research.* 2020 Jul 1;26(13):3307-3318.

The Devastation of Childhood Cancer

Cancer is the leading cause of death by disease for Australian children.

Worldwide
~400,000
children & adolescents
(aged 0–19) develop cancer
every year.

1,270
Australian children
and teens will be
diagnosed with
cancer in 2025.

In 2025,
144
children & adolescents
(aged 0–19) will die from
cancer in Australia.

In children and adolescents (0–19 years):
32% of cancers are leukaemia and other blood cancers.
23.5% are brain and other central nervous system tumours.
6% are sarcomas.

.....

Childhood cancer is not a single disease — there are more than 12 major types of paediatric cancers and over 100 subtypes.

In 70 years,
the FDA has only
approved **50**
drugs for paediatric
cancers. Whereas for
adults, **60** cancer
drugs are approved
every year.

Most current
standard treatments
of paediatric cancer
were approved over
30 years ago,
many before the
mid-1980's, and were
invariably discovered
and developed for
adult cancers.

Did you know?

Current treatments cause severe and often lifelong side effects, including problems with:

- + Emotions, reproduction, growth, development, hormones, learning, memory, heart, lung, dental, digestive system, hearing, vision, sexual development, and sexual function.
- + Most strikingly, they can cause secondary cancers.
- + Childhood cancer survivors report higher rates of pain, fatigue, and sleep difficulties compared with siblings and peers, all of which are associated with poorer quality of life.
- + Symptoms of post-traumatic stress disorder are well-documented for parents whose children have completed cancer treatment.

Childhood cancers
are very different to
adult cancers and
cannot generally be
prevented.

Financial Statements

Year ended 30 June 2025

ABN: 42 030 465 053



STATEMENT BY THE COMMITTEE OF MANAGEMENT


The Committee Members have determined that the Foundation is not a reporting entity, and that this special purpose financial report should be prepared in accordance with the accounting policies outlined in Note 1 to the financial report.

In the opinion of the Committee of Management, the accompanying financial reports:

1.
 - (a) The financial statements and notes are in accordance with Part 5 of the Associations Incorporation Act 2015; and
 - (b) The accompanying Operating Statement gives a true and fair view of the operating deficit of the Foundation for the financial year; and
 - (c) The accompanying Balance Sheet gives a true and fair view of the state of affairs of the Foundation as at the end of the financial year.
2. At the date of the statement there are reasonable grounds to believe that the Foundation will be able to pay its debts as and when they fall due.

This statement is made in accordance with a resolution of the Committee of Management and is signed by and on behalf of the Committee of Management by:


.....
Chief Executive Officer – Andrea Alexander


.....
Treasurer – Justin Bruce

Date: 06/11/2025

INDEPENDENT AUDIT REPORT

TO THE MEMBERS OF THE CHILDREN'S LEUKAEMIA & CANCER RESEARCH FOUNDATION (INC)

NICK DEL POPOLO
CHARTERED ACCOUNTANT
9 CARRINGTON STREET
NORTH PERTH, WA, 6006
Ph: 0419 922 776

6 November 2025

TO THE MEMBERS

THE CHILDREN'S LEUKAEMIA & CANCER RESEARCH FOUNDATION (INC)

We have audited the financial statements of Children's Leukaemia & Cancer Research Foundation (INC)(The Foundation) for the year ended 30 June 2025.

The Foundation's Management Committee are responsible for the preparation of the financial statements. We have conducted an independent audit of these financial statements in order to express an opinion on them to the members of the Foundation. The Management Committee's responsibility also includes such internal control as the Management Committee's determine necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

The audit has been conducted in accordance with Australian Auditing Standards to provide reasonable assurance as to whether the financial statements are free of material misstatement. Our procedures included examination, on a test basis, of evidence supporting the amounts and other disclosures in the financial statements, and the evaluation of accounting policies and significant accounting estimates. These procedures have been undertaken to form an opinion as to whether in all materials respects the financial statements are presented fairly in accordance with Australian Accounting Standards so as to present a view of the Foundation which is consistent with our understanding of its financial position and the results of its operations.

The financial statements include fundraising receipts. It has not been practicable to determine whether pledged monies from external fundraising activities have been received and banked through the Foundation's accounts.

The Audit opinion expressed in this report has been formed on the above basis.

INDEPENDENCE

In conducting our audit, we have complied with the independence requirements of the Australian professional ethical pronouncements.

AUDIT OPINION

In our opinion, the financial statements present fairly the financial position of Children's Leukaemia & Cancer Research Foundation (INC) as at 30 June 2025 and the results of its operations for the year ended 30 June 2025 in accordance with applicable Accounting Standards to the extent described in Note 1.

In addition;

- a. The financial statements satisfy the requirements of Part 5 of the Associations Incorporation Act 2015;
- b. We have been given all information, explanations and assistance necessary for the conduct of the Audit;
- c. The Foundation has kept financial records sufficient to enable financial statements to be prepared and audited;
- d. The Foundation has kept other records as required by Part 5 of the Associations Incorporation Act 2015

EMPHASIS OF MATTER- BASIS OF ACCOUNTING

We draw attention to Note 1 to the financial report, which describes the basis of accounting. As a result, the financial report may not be suitable for another purpose. Our audit opinion is not modified in respect of this matter.



Nick Del Popolo
Chartered Accountant
Registered Company Auditor

Liability limited by a scheme approved under professional standards legislation


AUDITOR'S INDEPENDENCE DECLARATION

TO THE COMMITTEE OF MANAGEMENT OF THE CHILDREN'S LEUKAEMIA & CANCER RESEARCH FOUNDATION (INC)

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2025 there have been no contraventions of:

i. Any applicable code of professional conduct in relation to the audit

Name of firm: N DEL POPOLO
Name of partner: N DEL POPOLO
Date: 1st July 2025
Address: 9 CARRINGTON STREET
NORTH PERTH WA 6006



Nick Del Popolo
Chartered Accountant
Registered Company Auditor

Operating Statement 01/07/2024 - 30/06/2025

Revenue	2024/2025	2023/2024
Subscriptions	\$2,445	\$4,870
Donations & Promotions	\$143,605	\$168,318
Community Activities	\$55,693	\$226,067
Fed & WA Govt Assistance	-	\$2,500
Georgia Lowry Project	-	\$273
Back on Track Program	\$59,391	\$847,938
Raffles & Direct Mail Campaigns	\$24,715	\$449,082
Schools & Associations	\$303	\$82
Social Enterprise	-	\$3,418
Commercial Support		
Rent/Outgoings on unit 11 and 12	\$29,580	-
VLT	\$43	\$130
Woolworths Australia	\$1,816	\$2,017
Grants & Gift in Wills		
Gift in Wills	\$194,421	\$95,701
Grants	\$18,000	-
Interest Received	\$3,562	\$105,055
TOTAL REVENUE	\$533,574	\$1,905,451
Expenditure	2024/2025	2023/2024
Admin, Staff & Other Costs	\$329,402	\$525,665
Back on Track Program	\$162,696	\$473,240
Depreciation	\$51,778	\$71,990
Market Value M/Mment (unrealised)	\$(71,006)	\$(13,517)
Raffles & Direct Mail Campaigns	\$2,400	\$270,087
Promotions & Events	\$6,786	\$108,260
Property Outgoings/Refurbishment	\$46,365	\$89,940
Social Enterprise	-	\$4,942
SUB-TOTAL	\$528,421	\$1,530,605
Appropriations	2024/2025	2023/2024
Research Funding/Grants		
Back on Track Foundation donation	\$573,026	-
PRO10111/20728 Block Grant - July 2024 to June 2025	\$281,442	\$892,922
PRO20514 Dr S Malinge - UR Kees Fellowship - July 2024 to June 2025	\$153,015	\$259,098
PRO21183 Program Manager for TKI Cancer Centre	-	\$101,587
SUB-TOTAL	\$1,007,483	\$1,253,607
EXCESS/(DEFICIT) TRANSFER TO ACCUMULATED FUNDS	\$(1,002,330)	\$(878,761)

The accompanying notes form part of the financial statements.

Balance Sheet 30/06/2024

Accumulated Funds	Notes	2024/2025	2023/2024
Balance as at 01/07/2022		\$2,474,801	\$3,353,562
Excess/(Deficit) from Operating Statement		\$(1,002,330)	\$(878,761)
TOTAL ACCUMULATED FUNDS		\$1,472,471	\$2,474,801
These Funds are represented by			
Current Assets	Notes	2024/2025	2023/2024
Cash on hand		-	\$150
Cash at bank		\$289,693	\$1,416,136
TOTAL CASH AVAILABLE		\$289,693	\$1,416,136
Trade Debtors		\$364	-
Shares at Cost		\$22,189	\$22,189
Change in Market Value		\$5,161	\$3,155
TOTAL CURRENT ASSETS		\$317,407	\$1,441,630
Non-Current Assets		2024/2025	2023/2024
Property - Land & Buildings			
Property Unit 3 / 100 Hay Street Subiaco	2	\$886,630	\$886,630
Property Units 11 & 12 / 100 Hay Street Subiaco	2	\$752,082	\$752,082
Provision for Depreciation (Units 11 & 12)		\$(37,604)	\$(18,802)
Capital Improvements		\$121,626	\$121,626
Less: Accum Deprecation		\$(63,854)	\$(54,732)
Provision for Diminution in Value		\$(296,586)	\$(290,586)
Provision for Depreciation (Unit 3)		\$(197,680)	\$(175,514)
Provision for Diminution in Value (Units 11 & 12)		\$75,000	-
Computer Equipment at Cost		\$37,902	\$37,902
Less: Accum Deprecation		\$(34,341)	\$(32,653)
Wages Overpayment		-	\$3,510
Collectables		\$2,199	\$2,199
TOTAL NON-CURRENT ASSETS		\$1,245,374	\$1,231,661
TOTAL ASSETS		\$1,562,781	\$2,673,291
Current Liabilities		2024/2025	2023/2024
Trade Creditors		\$(17,720)	\$(159,286)
Accrued/Sundry Creditors		\$(10,886)	-
Contract Liability		\$(38,000)	-
Leave Liability		\$(21,668)	\$(65,152)
Provision for AL/LSL on-costs		\$(3,033)	\$(13,000)
Total Years Tax Liabilities		\$997	\$38,948
TOTAL LIABILITIES		\$(90,310)	\$(198,490)
NET ASSETS		\$1,472,471	\$2,474,801

The accompanying notes form part of the financial statements.

Statement of Cash Flows as at 30 June 2025

Cash Flows From Operating Activities	Notes	2024/2025	2023/2024
Receipts from:			
Subscriptions		\$2,445	\$4,870
Donations and Promotions		\$145,420	\$171,398
Community Activities		\$139,476	\$1,074,135
Raffles and Direct Mail Campaigns		-	\$527,392
School and Associations		\$303	\$3,500
Grants & Gifts in Wills		\$250,421	\$98,201
Interest		\$3,561	\$104,265
Payments to clients, suppliers, employees and for research grants		\$(1,668,220)	\$(2,986,277)
NET CASH USED IN OPERATING ACTIVITIES	3	\$(1,126,594)	\$(1,002,515)
Cash Flows From Investing Activities			
		2024/2025	2023/2024
Payments for Property, Plant & Equipment		-	\$(683,900)
Withdrawal of Term Deposits		-	\$3,007,555
NET CASH USED IN INVESTING ACTIVITIES		-	\$2,323,655
Net change in cash and cash equivalents		\$(1,126,594)	\$1,321,140
Cash and cash equivalents, beginning of year		\$1,416,286	\$95,144
Cash and cash equivalents, end of year		\$289,692	\$1,416,284

The accompanying notes form part of the financial statements.

NOTE 1 - Statement of Significant Accounting Policies

The significant accounting policies which have been adopted in the preparation of this financial report are:

BASIS OF PREPARATION

The Financial Report is a special purpose financial report, which has been prepared to meet the requirements of the Management Committee to provide information to the Children's Leukaemia & Cancer Research Foundation (Inc). The Foundation is not a reporting entity and is not obliged to adhere to the mandatory reporting requirements of the Australian Accounting Standards. Notwithstanding the special reporting status of the foundation, the Management Committee have, unless otherwise stated followed generally accepted accounting principles in accordance with Australian Accounting Standards. The accounts have been prepared on the basis of historical costs and do not take into account the changing value of money. The Accounting policies are consistent with those prepared in 2024.

TAXATION AND GST

Children's Leukaemia & Cancer Research Foundation (Inc) is an income tax exempt body.

The Net amount of Goods and Services Tax and GST recoverable from or payable to the Australian Taxation Office is included as a current asset or liability in the Balance Sheet.

Revenue, Expenses and Assets are recognised net of GST.

EMPLOYEE ENTITLEMENTS

The amounts expected to be paid to employees for their pro-rata entitlement to long service leave and annual leave are accrued annually at current pay rates.

NOTE 2 - Valuation of Non-Current Assets - Property

Hay Street, Subiaco Unit 3 was purchased on 02/09/2010 and is valued at market valuation. The Market Valuation is at 27/08/2025 and is prepared by an independent licensed property valuer.

Hay Street, Subiaco Unit 11 and 12 was purchased on 26/07/2023 and is valued at market valuation. The Market Valuation is at 27/08/2025 and is prepared by an independent licensed property valuer.

NOTE 3 – Operating Cash Flow

Reconciliation of cash flows from operating activities with current year operating deficit.

	2024/2025	2023/2024
Net (deficit) / surplus for the year	\$(1,002,330)	\$(878,761)
Non-cash flows in operating excess:		
Deprecation	\$51,778	\$71,990
Diminution in share investments	\$(71,006)	\$(13,517)
Net (deficit)/surplus before working capital changes	\$(1,021,558)	\$(820,288)
Net changes in working capital:		
Change in trade and other receivables	\$(364)	\$(78,310)
Change in trade and other payables	\$(86,169)	\$(229,547)
Change in provisions	\$(15,500)	\$(30,990)
Net Cash From Operating activities	\$(1,126,591)	\$(1,002,515)





Make a difference
to the 1270 children
and adolescents (0-19)
**diagnosed with childhood
cancer every year in Australia.**

Please, donate today
ccrfgiving.au



Suite 3 / 100 Hay Street
Subiaco WA 6008

PO Box 1118
West Perth WA 6872



+(61) 8 9363 7400



admin@childcancerresearch.com.au
childcancerresearch.com.au